The purpose of unraveling the molecular pathways involved in p53 and RB aberrations in SCLC is to establish effective targeted therapies that will prolong the progression-free survival (PFS) and overall survival (OS) of these patients. The gene discussed is TP53; the disease is small cell lung carcinoma.